CD4+ T与CD8+ T淋巴细胞水平作为非小细胞肺癌免疫治疗预后因素的价值评估
Evaluation of CD4⁺ T and CD8⁺ T Lymphocyte Levels as Prognostic Factors for Immunotherapy in Non-Small Cell Lung Cancer
摘要: 免疫检查点抑制剂已成为非小细胞肺癌(NSCLC)的重要治疗手段，但现有生物标志物(如PD-L1表达、肿瘤突变负荷)存在异质性大、难以动态监测等局限，难以精准预测免疫治疗疗效。CD4+ T与CD8+ T淋巴细胞作为抗肿瘤免疫的核心细胞，其水平、比值及动态变化可能反映机体免疫状态，具有潜在的预后预测价值。本文梳理了外周血及肿瘤组织中CD4+ T与CD8+ T淋巴细胞及其亚群在NSCLC免疫治疗人群中的预后研究进展，探讨评估其作为NSCLC免疫治疗预后因素的临床价值。
Abstract: Immune checkpoint inhibitors have become a crucial therapeutic modality for non-small cell lung cancer (NSCLC). However, existing biomarkers—such as PD-L1 expression and tumor mutational burden—have limitations including high heterogeneity and difficulty in dynamic monitoring, which hamper their ability to accurately predict immunotherapeutic efficacy. CD4⁺ and CD8⁺ T lymphocytes, as core effector cells in antitumor immunity, may reflect the host immune status through their levels, ratios, and dynamic changes, thus holding potential prognostic and predictive value. This article reviews the current research progress on peripheral blood and tumor-infiltrating CD4⁺ and CD8⁺ T lymphocytes and their subpopulations in NSCLC patients receiving immunotherapy, and discusses their clinical utility as prognostic factors for immunotherapy in NSCLC.
文章引用：陈虹颖, 蒙筑. CD4+ T与CD8+ T淋巴细胞水平作为非小细胞肺癌免疫治疗预后因素的价值评估[J]. 临床医学进展, 2026, 16(7): 1731-1739. https://doi.org/10.12677/acm.2026.1672696

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] 国家卫生健康委办公厅. 原发性肺癌诊疗指南(2022年版) [J]. 协和医学杂志, 2022, 13(4): 549-570.
[3] Torabi, S., Yekzaman, E., Taherkhani, S., Talachi, N., Khoshravesh, R., Khosravi, A., et al. (2025) Immune Cell-Based Therapies for Solid Tumors, Current Challenges and Therapeutic Advances. Cell Communication and Signaling, 24, Article No. 73. [Google Scholar] [CrossRef] 
[4] Di Federico, A., Alden, S.L., Smithy, J.W., Ricciuti, B., Alessi, J.V., Wang, X., et al. (2024) Intrapatient Variation in PD-L1 Expression and Tumor Mutational Burden and the Impact on Outcomes to Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer. Annals of Oncology, 35, 902-913. [Google Scholar] [CrossRef] [PubMed]
[5] Uruga, H. and Mino-Kenudson, M. (2021) Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Lung Cancer: PD-L1 and Beyond. Virchows Archiv, 478, 31-44. [Google Scholar] [CrossRef] [PubMed]
[6] Pan, Y., Fu, Y., Zeng, Y., Liu, X., Peng, Y., Hu, C., et al. (2022) The Key to Immunotherapy: How to Choose Better Therapeutic Biomarkers for Patients with Non-Small Cell Lung Cancer. Biomarker Research, 10, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[7] Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[8] Liu, Y., Qin, D. and Fu, J. (2025) T Lymphocyte Heterogeneity in NSCLC: Implications for Biomarker Development and Therapeutic Innovation. Frontiers in Immunology, 16, Article ID: 1604310. [Google Scholar] [CrossRef] [PubMed]
[9] Yang, L., Geng, J., Yang, H., Zhao, M., Yuan, H., Yan, Y., et al. (2025) Closer Proximity of Pre-Treatment CD4+ T Cells to CD8+ T Cells Favor Response to Neoadjuvant Immunotherapy in Patients with PD-L1 Low-Expressing Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 14, 810-823. [Google Scholar] [CrossRef] [PubMed]
[10] Wen, H., Zhang, P., Zhao, J., Liu, Y., Wan, L., Li, H., et al. (2025) Metabolic Alterations Driven by LDHA in CD8 + T Cells Promote Immune Evasion and Therapy Resistance in NSCLC. Scientific Reports, 15, Article No. 24440. [Google Scholar] [CrossRef] [PubMed]
[11] Zhou, F. (2010) Perforin: More than Just a Pore-Forming Protein. International Reviews of Immunology, 29, 56-76. [Google Scholar] [CrossRef] [PubMed]
[12] Lee, S., Bar-Haim, E., Machlenkin, A., Goldberger, O., Volovitz, I., Vadai, E., et al. (2004) In Vivo Rejection of Tumor Cells Dependent on CD8 Cells That Kill Independently of Perforin and Fasl. Cancer Gene Therapy, 11, 237-248. [Google Scholar] [CrossRef] [PubMed]
[13] Liu, S., Meng, Y., Liu, L., Lv, Y., Yu, W., Liu, T., et al. (2022) CD4+ T Cells Are Required to Improve the Efficacy of CIK Therapy in Non-Small Cell Lung Cancer. Cell Death & Disease, 13, Article No. 441. [Google Scholar] [CrossRef] [PubMed]
[14] Zhong, T., Sun, S., Zhao, M., Zhang, B. and Xiong, H. (2025) The Mechanisms and Clinical Significance of CD8+ T Cell Exhaustion in Anti-Tumor Immunity. Cancer Biology & Medicine, 22, 460-480. [Google Scholar] [CrossRef] [PubMed]
[15] Liu, X., Xi, X., Xu, S., Chu, H., Hu, P., Li, D., et al. (2024) Targeting T Cell Exhaustion: Emerging Strategies in Non-Small Cell Lung Cancer. Frontiers in Immunology, 15, Article ID: 1507501. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, Y., Jiang, H., Li, Y., Wu, F., Chen, Z., Zheng, G., et al. (2025) Pre-Treatment Peripheral Blood TCR Repertoire as a Predictor of Response in Patients with NSCLC Treated with Immunochemotherapy. BMC Cancer, 25, Article No. 1105. [Google Scholar] [CrossRef] [PubMed]
[17] Laheurte, C., Dosset, M., Vernerey, D., Boullerot, L., Gaugler, B., Gravelin, E., et al. (2019) Distinct Prognostic Value of Circulating Anti-Telomerase CD4+ Th1 Immunity and Exhausted PD-1+/TIM-3+ T Cells in Lung Cancer. British Journal of Cancer, 121, 405-416. [Google Scholar] [CrossRef] [PubMed]
[18] Zheng, Q.M., Li, Y.Y., Wang, Y.P., et al. (2025) Prognostic Significance of CD4+ Tumour Infiltrating Lymphocytes in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors Therapy. Journal of the College of Physicians and Surgeons Pakistan, 35, 341-350. [Google Scholar] [CrossRef] [PubMed]
[19] Mao, X.D., Chen, S.Z., Shen, S.Q., et al. (2023) Clinical Significance of Regulatory T Cells and T Lymphocyte Subsets in Peripheral Blood in Neoadjuvant Chemotherapy for Breast Cancer. American Journal of Cancer Research, 13, 3091-3099.
[20] Dong, C., Feng, Y., Jiang, Y., et al. (2024) Relationship between Peripheral Blood T Lymphocyte Subsets and Prognosis of Patients with Advanced Non-Small Cell Lung Cancer Treated with Camrelizumab. Cancer Research on Prevention and Treatment, 51, 185-190.
[21] Li, G.X., Zheng, Q.M., Li, Y.Y., et al. (2025) Correlation of Peripheral Blood CD4/CD8 Ratio with Efficacy and Prognosis in Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors. Journal of the College of Physicians and Surgeons Pakistan, 35, 800-802.
[22] Yang, X., Li, Q. and Zeng, T. (2024) Peripheral CD4+ T Cells Correlate with Response and Survival in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemo-Immunotherapy. Frontiers in Immunology, 15, Article ID: 1364507. [Google Scholar] [CrossRef] [PubMed]
[23] Inomata, M., Matsumoto, M., Takata, N., Hayashi, K., Seto, Z., Hirai, T., et al. (2023) Peripheral CD4 Memory T Cells Predict the Efficacy of Immune Checkpoint Inhibitor Therapy in Patients with Non-Small Cell Lung Cancer. Scientific Reports, 13, Article No. 10807. [Google Scholar] [CrossRef] [PubMed]
[24] Du, X., Wen, S., Shi, R., Xia, J., Wang, R., Zhang, Y., et al. (2023) Peripheral Blood Lymphocytes Differentiation Patterns in Responses/Outcomes to Immune Checkpoint Blockade Therapies in Non-Small Cell Lung Cancer: A Retrospective Study. BMC Cancer, 23, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[25] Arasanz, H., Zuazo, M., Bocanegra, A., Gato, M., Martínez-Aguillo, M., Morilla, I., et al. (2020) Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 12, Article 344. [Google Scholar] [CrossRef] [PubMed]
[26] Miao, K., Zhang, X., Wang, H., Si, X., Ni, J., Zhong, W., et al. (2022) Corrigendum: Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Immunology, 13, Article ID: 912180. [Google Scholar] [CrossRef] [PubMed]
[27] Jia, Y., Wang, R., Shen, J., et al. (2025) Hematological Parameters as Predictors of Immune-Related Adverse Events: Risk Factor Analysis in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy. American Journal of Translational Research, 17, 4976-4985. [Google Scholar] [CrossRef] [PubMed]
[28] Guo, Q., Cai, J., Zhou, L. and Cai, L. (2026) Ki-67 with Neutrophil-to-Lymphocyte and CD4-Positive/CD8-Positive Ratios Predicts Early Response in Non-Small Cell Lung Cancer. Journal of Visualized Experiments, No. 229, e70014. [Google Scholar] [CrossRef] 
[29] Yin, T., Li, Y., Sun, Q., Yuan, Q., Zhu, S., Yu, J., et al. (2025) The Application of Peripheral Blood Immune Profiling in Personalized Treatment of Locally Advanced and Advanced Lung Cancer: A Nomogram Approach. Frontiers in Oncology, 15, Article ID: 1642829. [Google Scholar] [CrossRef] 
[30] Bai, X., Wang, X., Xu, H., Bai, Y., Chen, Q., Bi, S., et al. (2025) Combined Laboratory and Imaging Indicators to Construct Risk Models for Predicting Immunotherapy Efficacy and Prognosis in Non-Small Cell Lung Cancer: An Observational Study (STROBE Compliant). Medicine, 104, e45224. [Google Scholar] [CrossRef] 
[31] 袁胜芳, 姬泽萱, 任婕, 等. 淋巴细胞亚群绝对计数联合临床特征建立免疫治疗晚期非小细胞肺癌生存预测模型[J]. 国际呼吸杂志, 2025, 45(11): 941-950.
[32] Derraze, Y., Hashemi, S.M.S., Ulas, E.B., Ziesemer, K.A., Lissenberg-Witte, B., Radonic, T., et al. (2025) Evaluating the Significance of Combining PD-L1 and Tils as Biomarkers in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: A Systematic Review. BJC Reports, 3, Article No. 65. [Google Scholar] [CrossRef] 
[33] Ghorani, E., Reading, J.L., Henry, J.Y., Massy, M.R.D., Rosenthal, R., Turati, V., et al. (2020) The T Cell Differentiation Landscape Is Shaped by Tumour Mutations in Lung Cancer. Nature Cancer, 1, 546-561. [Google Scholar] [CrossRef] [PubMed]
[34] Hu-Lieskovan, S., Lisberg, A., Zaretsky, J.M., Grogan, T.R., Rizvi, H., Wells, D.K., et al. (2019) Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 25, 5061-5068. [Google Scholar] [CrossRef] [PubMed]
[35] Ghorani, E., Reading, J., Henry, J., Robert de Massy, M., Rosenthal, R., Turati, V., et al. (2020) P03.30 Tumur Mutations Drive Dysfunctional T Cell Differentiation in Lung Cancer. E-Poster Presentations, 8. [Google Scholar] [CrossRef] 
[36] Cheng, T., Zhang, J., Liu, D., Lai, G. and Wen, X. (2021) Prognosis of Non-Small-Cell Lung Cancer Patients with Lipid Metabolism Pathway Alternations to Immunotherapy. Frontiers in Genetics, 12, Article ID: 646362. [Google Scholar] [CrossRef] [PubMed]
[37] Shi, S., Wang, Y., Wu, J., Zha, B., Li, P., Liu, Y., et al. (2024) Predictive Value of PD-L1 and TMB for Short-Term Efficacy Prognosis in Non-Small Cell Lung Cancer and Construction of Prediction Models. Frontiers in Oncology, 14, Article ID: 1342262. [Google Scholar] [CrossRef] [PubMed]
[38] Horstman, I.M., Vinke, P.C., Suazo‐Zepeda, E., Hiltermann, T.J.N., Heuvelmans, M.A., Corpeleijn, E., et al. (2024) The Association of Nutritional and Inflammatory Biomarkers with Overall Survival in Patients with Non‐Small‐Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Thoracic Cancer, 15, 1764-1771. [Google Scholar] [CrossRef] [PubMed]
[39] Su, H., Yu, C., Sun, G., Wang, B., Gao, Y., Liu, X., et al. (2024) Prognostic Value of Immunotherapy in Advanced NSCLC Based on Baseline and Dynamic Changes in HALP. Biomolecules and Biomedicine, 25, 29-41. [Google Scholar] [CrossRef] [PubMed]
[40] 吕志芳, 王明, 程飞飞, 等. 中性粒细胞/淋巴细胞CD4+/CD8+与PD-1抑制剂免疫治疗肺癌疗效及OS的关系研究[J]. 河北医学, 2024, 30(9): 1483-1488.
[41] McLaughlin, Q., Sojka, D.K., Kennedy, K., Piersma, S.J. and Sethakorn, N. (2025) Unleashing NK Cells for Cancer Immunotherapy in Lung Cancer: Biologic Challenges and Clinical Advances. Journal of Experimental & Clinical Cancer Research, 44, Article No. 251. [Google Scholar] [CrossRef] [PubMed]
[42] Suzuki, H., Maruya, Y., Inomata, S., et al. (2025) Clinical Significance and Future Prospects of Tertiary Lymphoid Structure in Lung Cancer. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 52, 628-632.
[43] Song, L., Zeng, L., Xu, Q., Li, Y., Guo, W., Lin, S., et al. (2025) Lymphocyte Subset-Based Non-Invasive Biomarker Predicts Immunochemotherapy Efficacy in EGFR-TKI-Pretreated EGFR-Mutated NSCLC. iScience, 28, Article 113211. [Google Scholar] [CrossRef] [PubMed]
[44] Tuosto, L., Gelibter, A., Strigari, L., Asquino, A., Siringo, M., Pace, A., et al. (2026) The Immunological Fitness of NSCLC Patients Drives the Response to Anti-Pd1-Based Immunotherapy Regardless of Age. Journal of Translational Medicine, 24, Article No. 397. [Google Scholar] [CrossRef] 
[45] 赵豆豆, 齐晅, 黄博, 等. 感染性肺炎与免疫相关间质性肺病中淋巴细胞亚群的表达[J]. 北京大学学报(医学版), 2026, 58(3): 624-630.
[46] Albarracin Melo, L.T., Abdulkhakov, N., Han, I., El-Bizri, A., Brunner-Weinzierl, M., Schraven, B., et al. (2025) The Immunosuppressive Effect of Glucocorticoids in Human Primary T Cells Is Mainly Mediated via a Rapid Inhibition of the IL-2/IL-2R Signaling Axis. Cell Communication and Signaling, 23, Article No. 268. [Google Scholar] [CrossRef] [PubMed]

为你推荐